Acute liver failure requiring transplantation caused by ulipristal acetate.

Autor: Meunier L; Liver and Transplantation Unit, University Hospital Montpellier, Montpellier, France. Electronic address: lucy.meunier@chu-montpellier.fr., Meszaros M; Liver and Transplantation Unit, University Hospital Montpellier, Montpellier, France., Pageaux GP; Liver and Transplantation Unit, University Hospital Montpellier, Montpellier, France., Delay JM; Intensive Care Unit, DAR B, University Hospital Montpellier, Montpellier, France., Herrero A; Department of General and Liver Transplant Surgery, University Hospital Montpellier, Montpellier, France., Pinzani V; Department of Medical Pharmacology and Toxicology, CRPV, CHU Montpellier, University Montpellier, 34295 Montpellier, France., Dominique HB; Department of Medical Pharmacology and Toxicology, CRPV, CHU Montpellier, University Montpellier, 34295 Montpellier, France.
Jazyk: angličtina
Zdroj: Clinics and research in hepatology and gastroenterology [Clin Res Hepatol Gastroenterol] 2020 Jun; Vol. 44 (3), pp. e45-e49. Date of Electronic Publication: 2020 Mar 04.
DOI: 10.1016/j.clinre.2020.02.008
Abstrakt: Ulipristal has recently been suspected to be hepatotoxic by the European Medicines Agency but the evidence base for hepatotoxicity is sparse. This is a brief formal report of a patient administered ulipristal for 6-8 weeks and who developed acute liver failure leading to liver transplantation. The explanted liver showed extensive hepatocyte necrosis and inflammation compatible with drug-induced liver injury and cirrhosis. The usual causes of acute hepatitis and cirrhosis were eliminated. There were no other potential causative drugs. This case suggests that ulipristal may cause acute hepatitis, with pre-existing cirrhosis probably contributing to the severity of liver injury observed in this case. Ulipristal prescribers must remain vigilant and monitor liver function in their patients.
(Copyright © 2020 Elsevier Masson SAS. All rights reserved.)
Databáze: MEDLINE